肝门-窦血管疾病的研究进展

刘靓; 刘江凯; 刘甜恬; 张建文; 张雅儒; 李冰倩

doi:10.3969/j.issn.1001-5256.2022.10.034

肝门-窦血管疾病的研究进展

DOI: 10.3969/j.issn.1001-5256.2022.10.034

1.
河南中医药大学第一临床医学院，郑州 450000
2.
河南中医药大学第一附属医院脾胃肝胆科，郑州 450000

基金项目:

国家自然科学基金(联合基金) (U1504825);

河南省高等学校重点科研项目 (20A360014);

河南省中医药拔尖人才培养项目资助 (Yuwei TCM Letter No.15, 2021)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：刘靓负责课题设计，资料分析，撰写论文; 刘甜恬、张建文负责资料分析，整理文献; 张雅儒、李冰倩负责框架结构设计，修改参考文献; 刘江凯负责修改论文，指导撰写文章并最后定稿。

详细信息

通信作者:
刘江凯，xmlc001@126.com

计量
- 文章访问数: 654
- HTML全文浏览量: 778
- PDF下载量: 127
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-11
- 录用日期: 2022-04-13
- 出版日期: 2022-10-20

Research advances in porto-sinusoidal vascular disease

1.
The First Clinical Medical College of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China
2.
Department of Hepatology and Spleen-Stomach, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China

Research funding:

National Natural Science Foundation of China (Joint Fund) (U1504825);

Funding for Key Scientific Research Projects of Henan Universities (20A360014);

Training Projects for Talents of Top Traditional Chinese Medicine in Henan Province (Yuwei TCM Letter No.15, 2021)

More Information

Corresponding author: LIU Jiangkai, xmlc001@126.com(ORCID: 0000-0002-1529-5089)

摘要

摘要: 肝门-窦血管疾病(PSVD)于2017年被提议替代“特发性非肝硬化性门静脉高压症”，以描述在无肝硬化的情况下涉及门静脉或肝窦的典型组织学改变。根据PSVD的定义，存在肝病常见病因、门静脉血栓和无门静脉高压症的患者不再被排除在外。本文就PSVD的病因、临床表现、检查、诊断、治疗和预防等方面展开综述，以提高临床医生对该疾病的认识。
- 肝门-窦血管疾病 /
- 诊断 /
- 治疗学
Abstract: The term porto-sinusoidal vascular disease (PSVD) was proposed in 2017 to replace "idiopathic non-cirrhotic portal hypertension", so as to describe typical histological changes involving the portal vein or the hepatic sinus in the absence of liver cirrhosis. According to the definition of PSVD, patients with common causes of liver disease, portal vein thrombosis, and absence of portal hypertension are no longer excluded. This article reviews the etiology, clinical manifestations, examination, diagnosis, treatment, and prevention of PSVD, in order to improve the awareness of this disease among clinicians.
- Portal Vein-Sinus Vascular Disease /
- Diagnosis /
- Therapeutics

HTML全文

参考文献(42)

[1]	GUIDO M, SARCOGNATO S, SACCHI D, et al. Pathology of idiopathic non-cirrhotic portal hypertension[J]. Virchows Arch, 2018, 473(1): 23-31. DOI: 10.1007/s00428-018-2355-8.
[2]	GOEL A, RAMAKRISHNA B, ZACHARIAH U, et al. What makes non-cirrhotic portal hypertension a common disease in India? Analysis for environmental factors[J]. Indian J Med Res, 2019, 149(4): 468-478. DOI: 10.4103/ijmr.IJMR_1405_17.
[3]	DE GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
[4]	FIEL MI, SCHIANO TD. Idiopathic noncirrhotic portal hypertension[J]. Semin Diagn Pathol, 2019, 36(6): 395-403. DOI: 10.1053/j.semdp.2019.07.006.
[5]	KMEID M, LIU X, BALLENTINE S, et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: Review of current data[J]. Gastroenterology Res, 2021, 14(2): 49-65. DOI: 10.14740/gr1376.
[6]	ZHANG Y, YANG YF. Progress in the diagnosis and treatment of idiopathic non-cirrhotic portal hypertension[J]. Chin J Hepatol, 2021, 29(1): 87-91. DOI: 10.3760/cma.j.cn501113-20191201-00439. 张誉, 杨永峰. 特发性非硬化性门静脉高压诊治进展[J]. 中华肝脏病杂志, 2021, 29(1): 87-91. DOI: 10.3760/cma.j.cn501113-20191201-00439.
[7]	COTTE L, BÉNET T, BILLIOUD C, et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study[J]. J Hepatol, 2011, 54(3): 489-496. DOI: 10.1016/j.jhep.2010.07.030.
[8]	LEE H, REHMAN AU, FIEL MI. Idiopathic noncirrhotic portal hypertension: An appraisal[J]. J Pathol Transl Med, 2016, 50(1): 17-25. DOI: 10.4132/jptm.2015.09.23.
[9]	HERNÁNDEZ-GEA V, de GOTTARDI A, LEEBEEK FWG, et al. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis[J]. J Hepatol, 2019, 71(1): 175-199. DOI: 10.1016/j.jhep.2019.02.015.
[10]	KOOT BG, ALDERS M, VERHEIJ J, et al. A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension[J]. J Hepatol, 2016, 64(4): 974-977. DOI: 10.1016/j.jhep.2015.11.027.
[11]	VILARINHO S, SARI S, YILMAZ G, et al. Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension[J]. Hepatology, 2016, 63(6): 1977-1986. DOI: 10.1002/hep.28499.
[12]	ZUO C, CHUMBALKAR V, ELLS PF, et al. Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies[J]. Hepatol Int, 2017, 11(5): 452-460. DOI: 10.1007/s12072-017-9801-6.
[13]	BAFFY G. Origins of portal hypertension in nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2018, 63(3): 563-576. DOI: 10.1007/s10620-017-4903-5.
[14]	VAN DER GRAAFF D, KWANTEN WJ, COUTURIER FJ, et al. Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats[J]. Lab Invest, 2018, 98(10): 1263-1275. DOI: 10.1038/s41374-017-0018-z.
[15]	ELKRIEF L, RAUTOU PE. Idiopathic non-cirrhotic portal hypertension: the tip of the obliterative portal venopathies iceberg?[J]. Liver Int, 2016, 36(3): 325-327. DOI: 10.1111/liv.13048.
[16]	WÖRAN K, SEMMLER G, JACHS M, et al. Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(2): e251-e266. DOI: 10.1016/j.cgh.2020.11.039.
[17]	GIOIA S, NARDELLI S, PASQUALE C, et al. Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis[J]. Dig Liver Dis, 2018, 50(8): 839-844. DOI: 10.1016/j.dld.2018.01.132.
[18]	EELKRIEF L, FERRUSQUIA-ACOSTA J, PAYANCÉ A, et al. Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: A multicenter retrospective study[J]. Hepatology, 2019, 70(3): 911-924. DOI: 10.1002/hep.30628.
[19]	KLINE K, AL HANAYNEH M, BILAL M, et al. Portal vein thrombosis leading to pre-sinusoidal non-cirrhotic portal hypertension resulting in decreased synthetic function of the liver[J]. Gastroenterol Hepatol Bed Bench, 2019, 12(2): 174-177.
[20]	SAHIN A, ARTAS H, TUNC N, et al. Hematological indices in portal hypertension: Cirrhosis versus noncirrhotic portal hypertension[J]. J Clin Med, 2018, 7(8): 196. DOI: 10.3390/jcm7080196.
[21]	SUN Y, LAN X, SHAO C, et al. Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review[J]. J Gastroenterol Hepatol, 2019, 34(8): 1417-1423. DOI: 10.1111/jgh.14552.
[22]	RAJESH S, MUKUND A, SUREKA B, et al. Non-cirrhotic portal hypertension: an imaging review[J]. Abdom Radiol (NY), 2018, 43(8): 1991-2010. DOI: 10.1007/s00261-018-1570-8.
[23]	LIU HB, PIAO BG, LIU J. Progress in the imaging studies of idiopathic non-cirrhotic portal hypertension[J]. People's Military Surgeon, 2019, 62(7): 658-661. https://www.cnki.com.cn/Article/CJFDTOTAL-RMJZ201907023.htm 刘海博, 朴秉国, 刘静. 特发性非肝硬化门静脉高压症影像学研究进展[J]. 人民军医, 2019, 62(7): 658-661. https://www.cnki.com.cn/Article/CJFDTOTAL-RMJZ201907023.htm
[24]	ARORA A, SARIN SK. Multimodality imaging of obliterative portal venopathy: what every radiologist should know[J]. Br J Radiol, 2015, 88(1046): 20140653. DOI: 10.1259/bjr.20140653.
[25]	ELKRIEF L, LAZARETH M, CHEVRET S, et al. Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension[J]. Hepatology, 2021, 74(1): 364-378. DOI: 10.1002/hep.31688.
[26]	AHMAD AK, ATZORI S, TAYLOR-ROBINSON SD, et al. Spleen stiffness measurements using point shear wave elastography detects noncirrhotic portal hypertension in human immunodeficiency virus[J]. Medicine (Baltimore), 2019, 98(47): e17961. DOI: 10.1097/MD.0000000000017961.
[27]	NICOARǍ-FARCǍU O, RUSU I, STEFǍNESCU H, et al. Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease[J]. World J Gastroenterol, 2020, 26(22): 3000-3011. DOI: 10.3748/wjg.v26.i22.3000.
[28]	ZHANG Y, LIU H, DING HG. Early diagnosis of non-cirrhotic portal hypertension should be taken seriously[J]. Chin J New Clin Med, 2021, 14(8): 745-748. DOI: 10.3969/j.issn.1674-3806.2021.08.03. 张妍, 刘晖, 丁惠国. 重视非肝硬化门脉高压症的早期诊断[J]. 中国临床新医学, 2021, 14(8): 745-748. DOI: 10.3969/j.issn.1674-3806.2021.08.03.
[29]	ETZION O, TAKYAR V, NOVACK V, et al. Spleen and liver volumetrics as surrogate markers of hepatic venous pressure gradient in patients with noncirrhotic portal hypertension[J]. Hepatol Commun, 2018, 2(8): 919-928. DOI: 10.1002/hep4.1198.
[30]	SEIJO S, LOZANO JJ, ALONSO C, et al. Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension[J]. Am J Gastroenterol, 2013, 108(6): 926-932. DOI: 10.1038/ajg.2013.11.
[31]	AGGARWAL S, FIEL MI, SCHIANO TD. Obliterative portal venopathy: a clinical and histopathological review[J]. Dig Dis Sci, 2013, 58(10): 2767-2776. DOI: 10.1007/s10620-013-2736-4.
[32]	JHARAP B, van ASSELDONK DP, de BOER NK, et al. Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low interobserver agreement[J]. PLoS One, 2015, 10(6): e0120299. DOI: 10.1371/journal.pone.0120299.
[33]	GUIDO M, ALVES VAF, BALABAUD C, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition[J]. Histopathology, 2019, 74(2): 219-226. DOI: 10.1111/his.13738.
[34]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VⅡ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[35]	SIRAMOLPIWAT S, SEIJO S, MIQUEL R, et al. Idiopathic portal hypertension: natural history and long-term outcome[J]. Hepatology, 2014, 59(6): 2276-2285. DOI: 10.1002/hep.26904.
[36]	LV Y, LI K, HE C, et al. TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosis[J]. Aliment Pharmacol Ther, 2019, 49(7): 926-939. DOI: 10.1111/apt.15186.
[37]	HE FL, QI RZ, ZHANG YN, et al. Transjugular intrahepatic portosystemic shunt and splenectomy are more effective than endoscopic therapy for recurrent variceal bleeding in patients with idiopathic noncirrhotic portal hypertension[J]. World J Clin Cases, 2020, 8(10): 1871-1877. DOI: 10.12998/wjcc.v8.i10.1871.
[38]	REGNAULT D, D'ALTEROCHE L, NICOLAS C, et al. Ten-year experience of transjugular intrahepatic portosystemic shunt for noncirrhotic portal hypertension[J]. Eur J Gastroenterol Hepatol, 2018, 30(5): 557-562. DOI: 10.1097/MEG.0000000000001067.
[39]	ANAND U, KUMAR R, PRIYADARSHI RN, et al. Proximal splenorenal shunt surgery for bleeding gastric varices in non-cirrhotic portal hypertension[J]. Cureus, 2020, 12(9): e10464. DOI: 10.7759/cureus.10464.
[40]	IRAWAN H, MULYAWAN IM. Combination of modified Sugiura technique and proximal splenorenal shunt for the management of portal vein thrombosis in noncirrhotic portal hypertension[J]. Clin Exp Gastroenterol, 2019, 12: 149-156. DOI: 10.2147/CEG.S188200.
[41]	OZTURK O, ELDEM G, PEYNIRCIOGLU B, et al. Outcomes of partial splenic embolization in patients with massive splenomegaly due to idiopathic portal hypertension[J]. World J Gastroenterol, 2016, 22(43): 9623-9630. DOI: 10.3748/wjg.v22.i43.9623.
[42]	MA B, ZHANG Y, ZHANG XX, et al. Liver transplantation for idiopathic portal hypertension: A case report[J]. J Clin Hepatol, 2020, 36(10): 2288-2290. DOI: 10.3969/j.issn.1001-5256.2020.10.028. 马博, 张雨, 张晓雪, 等. 特发性门静脉高压症肝移植1例报告[J]. 临床肝胆病杂志, 2020, 36(10): 2288-2290. DOI: 10.3969/j.issn.1001-5256.2020.10.028.